COMPANY

Bioprovar Corporation

HQ: Houston, TX source · bioprovar.com ↗ · Southwest

Location: Houston, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $349K (SBIR Phase II 5U44AG074105-03, continuation, notice Aug 14, 2026). NIH RePORTER 5U44AG074105-03 (Aug 14, 2026)
Evidence (1 event)
- Aug 14, 2026 · NIH RePORTER 5U44AG074105-03
  Organization: BIOPROVAR CORPORATION; City/State: HOUSTON, TX; Project number: 5U44AG074105-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 349073; Administering IC: National Institute on Aging; Project title: An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 14, 2026 Grant Government grant — SBIR: $349,073 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 15, 2025 Grant Government grant — SBIR: $484,680 (annual award, as published), announced Sep 15, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Aug 11, 2025 Grant Government grant — SBIR: $178,503 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Last 2 years.

Aug 14, 2026 Government grant — SBIR: $349,073 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 15, 2025 Government grant — SBIR: $484,680 (annual award, as published), announced Sep 15, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Aug 11, 2025 Government grant — SBIR: $178,503 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Annual award amounts. Total $597K.

Sep 20, 2024 NIH award 1R43AG087800-01A1 FY2024: $221,111 awarded for that fiscal year; activity R43 (SBIR); PI ROUSSEL, EUGENE; recipient as written: BIOPROVAR CORPORATION, HOUSTON, TX. An Innovative Immune Therapy Targeting the source ↗
Sep 22, 2021 NIH award 1U44AG074105-01 FY2021: $376,045 awarded for that fiscal year; activity U44 (SBIR); PI ROUSSEL, EUGENE; recipient as written: BIOPROVAR CORPORATION, HOUSTON, TX. An Innovative Immune Therapy with Antibiotic source ↗